Statement: the primary trial does not record any cardiac related adverse events.
Primary_evidence: Adverse Events 1:   Total: 112/458 (24.45%)   Febrile neutropenia 8/458 (1.75%)   Neutropenia 6/458 (1.31%)   Anaemia 3/458 (0.66%)   Thrombocytopenia 3/458 (0.66%)   Pancytopenia 2/458 (0.44%)   Myocardial infarction 0/458 (0.00%)   Pericardial effusion 0/458 (0.00%)   Tachycardia 0/458 (0.00%)   Acute myocardial infarction 1/458 (0.22%)   Atrial fibrillation 0/458 (0.00%) Adverse Events 2:   Total: 39/221 (17.65%)   Febrile neutropenia 5/221 (2.26%)   Neutropenia 1/221 (0.45%)   Anaemia 2/221 (0.90%)   Thrombocytopenia 0/221 (0.00%)   Pancytopenia 0/221 (0.00%)   Myocardial infarction 2/221 (0.90%)   Pericardial effusion 2/221 (0.90%)   Tachycardia 2/221 (0.90%)   Acute myocardial infarction 0/221 (0.00%)   Atrial fibrillation 1/221 (0.45%)